Comprehensive in silico Study of GLUT10: Prediction of Possible Substrate Binding Sites and Interacting Molecules.
The Arterial Tortuosity Syndrome (ATS) is an autosomal recessive connective tissue disorder, mainly characterized by tortuosity and stenosis of the arteries with a propensity towards aneurysm formation and dissection. It is caused by the mutations in the SLC2A10 gene, which encodes the facilitative glucose transporter GLUT10. The molecules transported by and interacting with GLUT10 are still not unambiguously identified, hence the study attempted to identify both the substrate binding site of GLUT10 and the molecules interacting with this site. As High-resolution X-ray crystallographic structure of GLUT10 is not available; 3D homology model of GLUT10 in open conformation was constructed. Further molecular docking and bioinformatics investigation was employed. Blind docking of nine reported potential in vitro substrates with this 3D homology model revealed that possible substrate binding site is made with PRO531, GLU507, GLU437, TRP432, ALA506, LEU519, LEU505, LEU433, GLN525, GLN510, LYS372, LYS373, SER520, SER124, SER533, SER504, SER436 amino acid residues. Virtual screening of all metabolites from the Human Serum Metabolome Database against the GLUT10 homology model disclosed possible substrates and interacting molecules for GLUT10, which are mostly lipid and biliary secretion compounds, some of which are found to be involved directly or partially in ATS progress. Reported mutation screening revealed that a highly emergent point mutation (c. 1309G>A, p.Glu437Lys) is located in the predicted substrate binding site region. Virtual screening expands this possibility to explore more compounds that can interact with GLUT10 and may aid in understanding the mechanisms leading to ATS.